커넥티드 약물전달 디바이스 시장 : 디바이스 유형별, 접속 형태별, 투여 경로별, 치료 영역별, 지역별 : 업계 동향과 세계 예측(-2035년)

Connected Drug Delivery Devices Market by Type of Device, Mode of Connectivity, Route of Administration, Therapeutic Area, and Geographical Regions: Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,943,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,126,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,335,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 커넥티드 약물전달 디바이스 시장 규모는 2035년까지의 예측 기간 중 10.1%의 CAGR로 확대하며, 현재 44억 달러에서 2035년까지 127억 달러로 성장할 것으로 예측됩니다.

현재 전 세계 의료비 부담의 상당 부분은 환자가 처방받은 약물을 제대로 복용하지 않는 데서 기인합니다. 복약 순응도 저조는 무작위 임상시험 결과와 실제 건강 데이터(임상 현장 밖에서 파악된 데이터)가 불일치하는 주요 원인 중 하나입니다. 세계보건기구(WHO)에 따르면 인구의 3분의 2가 최소 한 가지 이상의 약물을 처방받고 있습니다. 이 중 약 50%의 환자가 의사의 처방대로 치료 요법을 준수하지 않는 것으로 추정됩니다. 환자의 복약 불이동에 영향을 미치는 요인으로는 약물 및 의료 서비스 이용과 관련된 문제, 복잡한 투약 스케줄을 이해하지 못하는 것 등이 있습니다.

수년 동안 다양한 제약회사와 의료 서비스 프로바이더들은 환자의 치료 요법 순응도를 개선하기 위해 여러 가지 전략을 개발해 왔습니다. 그 중 최근 수년간 인기를 끌고 있는 것은 커넥티드/스마트 약물전달 장비 및 기타 디지털 헬스 솔루션으로, 환자와 의료진이 환자의 약물 복용을 추적할 수 있게 함으로써 복약 순응도를 향상시키는 데 기여하고 있습니다. 기여하고 있습니다. 주목할 점은 커넥티드/스마트 약물전달 장비와 인공지능 및 블록체인과 같은 신기술을 통합함으로써 이러한 장비의 잠재력을 더욱 향상시킬 수 있다는 점입니다. 정확하고 효과적인 디지털 헬스 솔루션에 대한 수요 증가와 기술 발전(원격의료 플랫폼과의 통합)으로 인해 세계 커넥티드 약물전달 장비 시장은 향후 꾸준한 성장세를 보일 것으로 예상됩니다.

세계의 커넥티드 약물전달 디바이스 시장에 대해 조사했으며, 시장의 개요와 디바이스 유형별, 접속 형태별, 투여 경로별, 치료 영역별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 서문

제2장 조사 방법

제3장 시장 역학

제4장 경제 및 기타 프로젝트 특유의 고려 사항

제5장 개요

제6장 서론

제7장 시장 구도 : 커넥티드/스마트 약물전달 디바이스

제8장 시장 구도 : 애드온 센서

제9장 제품 경쟁력 분석

제10장 기업 개요 : 북미에 거점을 두는 커넥티드/스마트 약물전달 디바이스 제조업체

제11장 기업 개요 : 유럽에 거점을 두는 커넥티드/스마트 약물전달 디바이스 제조업체

제12장 기업 개요 : 아시아태평양 및 기타 지역에 거점을 두는 커넥티드/ 스마트 약물전달 디바이스 제조업체

제13장 임상시험 분석

제14장 파트너십과 협업

제15장 자금조달과 투자

제16장 밸류체인/비용 가격 분석

제17장 커넥티드/스마트 약물전달 디바이스의 규제 상황

제18장 사례 연구 : 복약 순응도를 개선하기 위한 커넥티드 약물전달 디바이스의 응용

제19장 SWOT 분석

제20장 세계의 커넥티드 약물전달 디바이스 시장

제21장 커넥티드 약물전달 디바이스 시장, 디바이스 유형별

제22장 커넥티드 약물전달 디바이스 시장, 접속 형태별

제23장 커넥티드 약물전달 디바이스 시장, 투여 경로별

제24장 커넥티드 약물전달 디바이스 시장, 치료 영역별

제25장 커넥티드 약물전달 디바이스 시장, 지역별

제26장 결론

제27장 이그제큐티브 인사이트

• 장의 개요
• Phillips-Medisize
• Cognita Labs
• Portal Instruments
• Enable Injections
• Amiko
• Elcam Medical
• West Pharmaceutical Services
• Avoset Health(acquired by Eitan Medical)
• Phillips-Medisize
• Sorrel Medical etectRx

제28장 부록 1 : 표 형식 데이터

제29장 부록 2 : 기업·단체 리스트

제30장 부록 3 : 파트너십과 협력, 2015년 이후

KSA

영문 목차

영문목차

CONNECTED DRUG DELIVERY DEVICES MARKET: OVERVIEW

As per Roots Analysis, the global connected drug delivery devices market is estimated to grow from USD 4.4 billion in the current year to USD 12.7 billion by 2035, at a CAGR of 10.1% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Device

• Connected / Smart Wearable Injectors
• Connected / Smart Inhalers
• Connected / Smart Pen Injectors
• Connected / Smart Autoinjectors
• Connected / Smart Needle-free Injection Systems

Mode of Connectivity

• Bluetooth-enabled Devices
• Near Field Communication-enabled Devices
• Cellular-enabled Devices
• Wide Area Network-enabled Devices

Route of Administration

• Parenteral
• Inhalational

Therapeutic Area

• Metabolic Disorders
• Respiratory Disorders
• Autoimmune Disorders
• Other Disorders

Key Geographical Regions

• North America (US and Canada)
• Europe (UK, Germany, France, Italy, Spain and Rest of the Europe)
• Asia-Pacific (China, India, Japan and Rest of the Asia-Pacific)
• Middle East and North Africa (Egypt, Israel, Argentina and Rest of the Middle East and North Africa)
• Latin America and Rest of the World (Brazil, Argentina and Rest of the World)

CONNECTED DRUG DELIVERY DEVICES MARKET: GROWTH AND TRENDS

Currently, a significant proportion of the global healthcare burden is being attributed to non-adherence to the medication that is prescribed to patients. Poor medication adherence is one of the leading causes of discrepancies between results obtained from randomized clinical studies and real-world health data (captured outside clinical settings). According to the World Health Organization (WHO), two-thirds of the population is prescribed at least one medication. Of these, an estimated 50% of the patients do not follow the treatment regimen as prescribed by the doctors. Some of the factors that have influenced non-adherence amongst the patient population include challenges linked to accessing medications and healthcare services, and the inability to understand complex dosing schedules.

Over the years, several strategies have been developed by various pharmaceutical companies and healthcare providers to improve patient compliance towards their treatment regimens. One such alternative that has gained popularity in the last few years is connected / smart drug delivery devices and other digital health solutions that enable patients / healthcare providers to track the medication activity of patients and thereby, help improve drug adherence. Notably, the integration of connected / smart drug delivery devices with emerging technologies, such as artificial intelligence and blockchain can further enhance the prospects for these devices. With the growing demand for accurate and effective digital health solutions and advancement in technologies (integration with telehealth platforms), the global connected drug delivery devices market is poised to witness steady growth, in the foreseen future.

CONNECTED DRUG DELIVERY DEVICES MARKET: KEY INSIGHTS

The report delves into the current state of the connected drug delivery devices market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 85 connected / smart drug delivery devices have been launched / approved or are currently under development; notably, the market landscape features the presence of both established players and new entrants.

2. Smart wearable injectors emerged as the most prominent connected drug delivery device; further, majority of these devices are intended for the administration of medications via subcutaneous route.

3. At present, 30 innovative add-on sensors are available / under development for integration with conventional drug delivery devices; most of the add-on sensor manufacturers are start-ups based in Europe.

4. Close to 50% of the add-on sensors are compatible with inhalers; of these, more than 55% can support all three features, namely audio / visual alerts, bluetooth connectivity and companion mobile application.

5. In pursuit of gaining a competitive edge, stakeholders are actively enhancing their existing capabilities by improving their respective product portfolios and complying to the evolving industry standards.

6. Several clinical trials have been registered related to connected / smart drug delivery devices, across different geographies.

7. More than 25% of the deals related to connected / smart drug delivery devices were inked in the last three years; majority of the intercontinental deals were signed by players based in North America.

8. Several investors have realized the opportunity within the domain by investing multi-billion dollars in the past few years; further, majority of the amount was raised by players based in North America.

9. By analyzing the key drivers and barriers affecting the evolution of connected drug delivery devices market, valuable insights can be generated regarding current and future opportunities within this domain.

10. Owing to the ability of connected drug delivery devices to provide precise dosing and remote patient monitoring, the market is anticipated to witness an annualized growth of 10.1% over the next decade.

CONNECTED DRUG DELIVERY DEVICES MARKET: KEY SEGMENTS

Currently, Connected / Smart Wearable Injectors Segment Holds the Maximum Share of the Connected Drug Delivery Devices Market

Based on the type of device, the market is segmented into connected / smart wearable injectors, connected / smart inhalers, connected / smart pen injectors, connected / smart autoinjectors and connected / smart needle-free injection systems. It is worth highlighting that the current connected drug delivery devices market is dominated by connected / smart wearable injectors. This trend is likely to remain the same in the near future. This can be attributed to the growing prevalence of chronic conditions and the continuous efforts of stakeholders to develop advanced devices.

Connected Drug Delivery Devices Supporting Bluetooth are Likely to Dominate the Connected Drug Delivery Devices Market During the Forecast Period

Based on the mode of connectivity, the market is segmented into Bluetooth-enabled devices, near field communication-enabled devices, cellular-enabled devices, and wide area network-enabled devices. The current market is expected to be driven by connected drug delivery devices supporting Bluetooth and a similar trend is anticipated in the long term. This can be attributed to the widespread adoption of Bluetooth connectivity due to its easy setup process, absence of any need for additional equipment and universal availability on smartphones. Additionally, the reliability and established presence of Bluetooth technology in the market make it a trusted choice for patients seeking connectivity solutions.

Inhalational Route is the Fastest Growing Segment of the Connected Drug Delivery Devices Market During the Forecast Period

Based on the route of administration, the market is segmented into parenteral and inhalational. It is anticipated that the devices delivering drugs via inhalational route are likely to grow at a higher CAGR during the forecast period. This can be attributed to the fact that administration of drugs via inhalational route is flexible, painless, and offers sustained localized action.

Metabolic Disorders Segment Accounts for the Largest Share of the Connected Drug Delivery Devices Market

Based on the therapeutic area, the market is segmented into metabolic disorders, respiratory disorders, autoimmune disorders and other disorders. While metabolic disorders account for a relatively higher market share, it is worth highlighting that the autoimmune disorders segment is expected to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe and Asia-Pacific. Majority share is expected to be captured by North America and Europe. It is worth highlighting that over the years, the market for Asia-Pacific is expected to grow at a higher CAGR. This can be attributed to the growing research and development activity for novel drug delivery solutions, the increasing number of biopharmaceutical start-ups and the upcoming device approvals in the region.

Example Players in the Connected Drug Delivery Devices Market

• Bigfoot Biomedical
• BIOCORP
• Eitan Medical
• E3D Elcam Drug Delivery Device
• EoFlow
• Gerresheimer
• Insulet
• Medtronic
• Medtrum
• Nemera
• Phillips-Medisize
• Roche
• Sonceboz
• SOOIL Development
• Tandem Diabetes Care
• West Pharmaceutical Services
• Ypsomed

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Senior Director, Global Strategic Marketing, Medical, Phillips-Medisize
• Co-founder and Chief Executive Officer, Cognita Labs
• Founder and Chief Executive Officer, Portal Instruments
• Chief Executive Officer and President, Enable Injections
• Chief Executive Officer, Amiko
• Vice President and Chief Scientist, Elcam Medical
• Director (Global Communications) and Graham Reynolds, Former Vice President (Strategic Partnerships and Business Development), West Pharmaceutical Services
• Former Chief Executive Officer, Avoset Health (acquired by Eitan Medical)
• Former Director (Front-end Innovation and Head of Connected Health), Phillips-Medisize
• Former Vice President (Marketing and Alliance Management), Sorrel Medical (acquired by LTS lohmann therapie-systeme)
• Advisor (Strategy and Business Development), etectRx

CONNECTED DRUG DELIVERY DEVICES MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the connected drug delivery devices market, focusing on key market segments, including [A] type of device, [B] mode of connectivity, [C] route of administration, [D] therapeutic area and [E] key geographical regions.
• Market Landscape (Connected / Smart Drug Delivery Devices): A comprehensive evaluation of integrated connected drug delivery devices, considering various parameters, such as [A] stage of development, [B] launch year of device, [C] type of integrated device, [D] route of administration, [E] therapeutic area, [F] target indication, [G] key features, [H] mode of connectivity, [I] availability of companion mobile application and [J] availability of data storage / cloud platform. In addition, it also includes tabulated information on regulatory approvals, geographical reach and drugs compatible with connected / smart drug delivery devices. Further, the chapter provides a detailed list of companies engaged in manufacturing connected drug delivery devices, along with detailed analysis based on various parameters, such as [K] year of establishment, [L] company size (in terms of employee count), [M] location of headquarters and [N] most active players (in terms of the number of integrated connected drug delivery devices manufactured).
• Market Landscape (Add-on Sensors): A comprehensive evaluation of add-on sensors, considering various parameters, such as [A] stage of development, [B] launch year of device, [C] compatible device, [D] route of administration, [E] therapeutic area, [F] target indication, [G] key features, [H] mode of connectivity, [I] availability of companion mobile application and [J] availability of data storage / cloud platform. It also includes detailed information on regulatory approvals, geographical reach and drugs that can be delivered using add-on sensors (in combination with conventional drug delivery devices). In addition, it provides a detailed list of companies engaged in manufacturing add-on sensors for drug delivery devices, along with detailed analysis based on various parameters, such as [K] year of establishment, [L] company size (in terms of employee count), [M] location of headquarters and [N] most active players (in terms of the number of add-on sensors manufactured).
• Product Competitiveness Analysis: A comprehensive competitive analysis of connected drug delivery devices and add-on sensors, examining factors, such as manufacturer strength and portfolio strength.
• Company Profiles: In-depth profiles of key connected drug delivery device providers, based in North America, Europe and Asia-Pacific, focusing on [A] company overviews, [B] financial information (if available), [C] product portfolio, [D] recent developments, and [F] an informed future outlook.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various connected drug delivery devices based on parameters like [A] trial registration year, [B] enrolled patient population, [C] trial phase, [D] trial status, [E] type of device, [F] type of sponsor / collaborator, [G] therapeutic area, [H] study design, [I] leading industry players (based on number of clinical trials), [J] leading connected / smart drug delivery devices (based on number of clinical trials) and [K] geography.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2020, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] class of device, [D] type of integrated device, [E] compatible device [F] most active players (in terms of number of partnerships signed) and [G] regional distribution.
• Funding and Investment Analysis: A detailed evaluation of the investments made in the connected drug delivery devices domain, based on several parameters, such as [A] year of funding, amount invested (USD million), [B] type of funding, [C] class of device, [D] geography, [E] most active players (in terms of number of funding instances and amount raised), and [F] most active investors (in terms of number of funding instances).
• Value Chain Analysis: A comprehensive value chain analysis that explores the various stages involved in the development of connected or smart drug delivery devices. This includes a discussion on research and development (R&D), product manufacturing and assembly, distribution, marketing and sales, and post-market surveillance, as well as details on the cost requirements at each of these stages.
• Case Study: Detailed case studies on two most common indications (namely asthma and diabetes), featuring a brief description of the disease, its epidemiology, economic burden (imposed due to non-adherence to prescribed treatments), and a summary of the evolution of drug delivery devices and other strategies focused on improving therapy adherence among patients suffering from the indication.
• Regulatory Landscape: A discussion on general regulatory guidelines issued by major regulatory bodies for the approval of connected drug delivery devices, across different countries / geographical regions.
• SWOT Analysis: A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry's evolution. Further, it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Key Market Segmentation
• 3.7. Robust Quality Control
• 3.8. Limitations

4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Overview of Major Currencies Affecting the Market
    • 4.2.2.2. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Exchange Impact
    • 4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Medication Adherence
  • 6.2.1. Digital Tools for Improving Medication Adherence
• 6.3. Overview of Connected / Smart Drug Delivery Devices
• 6.4. Key Design Features and Development Process
• 6.5. Classification of Connected / Smart Drug Delivery Devices
  • 6.5.1. Type of Device
    • 6.5.1.1. Connected Inhalers
    • 6.5.1.2. Connected Handheld Injectors
    • 6.5.1.3. Smart Pills
    • 6.5.1.4. Smart Implantable Devices
  • 6.5.2. Type of Technology
• 6.6. Regulatory Guidelines for Connected / Smart Drug Delivery Devices
• 6.7. Advantages and Limitations of Connected / Smart Drug Delivery Devices
• 6.8. Impact of COVID-19 on Connected / Smart Drug Delivery Devices Domain
• 6.9. Future Perspectives

7. MARKET LANDSCAPE: CONNECTED / SMART DRUG DELIVERY DEVICES

• 7.1. Chapter Overview
• 7.2. Connected / Smart Drug Delivery Devices: Overall Market Landscape
  • 7.2.1. Analysis by Stage of Development
  • 7.2.2. Analysis by Launch Year
  • 7.2.3. Analysis by Type of Integrated Device
  • 7.2.4. Analysis by Route of Administration
  • 7.2.5. Analysis by Therapeutic Area
  • 7.2.6. Analysis by Target Indication
  • 7.2.7. Analysis by Key Features
  • 7.2.8. Analysis by Mode of Connectivity
  • 7.2.9. Analysis by Availability of Companion Mobile Application
  • 7.2.10. Analysis by Availability of Data Storage / Cloud Platform
• 7.3. Connected / Smart Drug Delivery Device Manufacturers: Overall Market Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters
  • 7.3.4. Analysis by Year of Establishment and Location of Headquarters
  • 7.3.5. Analysis by Company Size and Location of Headquarters
  • 7.3.6. Most Active Players: Analysis by Number of Connected / Smart Drug Delivery Devices Manufactured

8. MARKET LANDSCAPE: ADD-ON SENSORS

• 8.1. Chapter Overview
• 8.2. Add-on Sensors: Overall Market Landscape
  • 8.2.1. Analysis by Stage of Development
  • 8.2.2. Analysis by Launch Year
  • 8.2.3. Analysis by Compatible Device
  • 8.2.4. Analysis by Route of Administration
  • 8.2.5. Analysis by Therapeutic Area
  • 8.2.6. Analysis by Target Indication
  • 8.2.7. Analysis by Key Features
  • 8.2.8. Analysis by Mode of Connectivity
  • 8.2.9. Analysis by Availability of Companion Mobile Application
  • 8.2.10. Analysis by Availability of Data Storage / Cloud Platform
• 8.3. Add-on Sensor Manufacturers: Overall Market Landscape
  • 8.3.1. Analysis by Year of Establishment
  • 8.3.2. Analysis by Company Size
  • 8.3.3. Analysis by Location of Headquarters
  • 8.3.4. Analysis by Year of Establishment and Location of Headquarters
  • 8.3.5. Analysis by Company Size and Location of Headquarters
  • 8.3.6. Most Active Players: Analysis by Number of Add-on Sensors Manufactured

9. PRODUCT COMPETITIVENESS ANALYSIS

• 9.1. Chapter Overview
• 9.2. Assumptions and Key Parameters
• 9.3. Methodology
• 9.4. Connected Drug Delivery Devices and Add-on Sensors: Product Competitiveness Analysis
  • 9.4.1. Connected / Smart Drug Delivery Devices
    • 9.4.1.1. Smart Handheld Injectors (Peer Group 1a)
    • 9.4.1.2. Smart Wearable Injectors (Peer Group 1b)
    • 9.4.1.3. Other Integrated Devices (Peer Group 1c)
  • 9.4.2. Add-on Sensors ((Peer Group 2)

10. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN NORTH AMERICA

• 10.1. Chapter Overview
• 10.2. Leading Connected / Smart Drug Delivery Device Manufacturers
  • 10.2.1. Medtronic
    • 10.2.1.1. Company Overview
    • 10.2.1.2. Financial Information
    • 10.2.1.3. Connected / Smart Drug Delivery Devices Portfolio
    • 10.2.1.4. Recent Developments and Future Outlook
  • 10.2.2. Insulet
    • 10.2.2.1. Company Overview
    • 10.2.2.2. Financial Information
    • 10.2.2.3. Connected / Smart Drug Delivery Devices Portfolio
    • 10.2.2.4. Recent Developments and Future Outlook
  • 10.2.3. Tandem Diabetes Care
    • 10.2.3.1. Company Overview
    • 10.2.3.2. Financial Information
    • 10.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
    • 10.2.3.4. Recent Developments and Future Outlook
• 10.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
  • 10.3.1. Bigfoot Biomedical
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
  • 10.3.2. Phillips-Medisize
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Connected / Smart Drug Delivery Devices Portfolio
  • 10.3.3. West Pharmaceutical Services
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Connected / Smart Drug Delivery Devices Portfolio

11. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN EUROPE

• 11.1. Chapter Overview
• 11.2. Leading Connected / Smart Drug Delivery Device Manufacturers
  • 11.2.1. BIOCORP
    • 11.2.1.1. Company Overview
    • 11.2.1.2. Financial Information
    • 11.2.1.3. Connected / Smart Drug Delivery Devices Portfolio
    • 11.2.1.4. Recent Developments and Future Outlook
  • 11.2.2. Gerresheimer
    • 11.2.2.1. Company Overview
    • 11.2.2.2. Financial Information
    • 11.2.2.3. Connected / Smart Drug Delivery Devices Portfolio
    • 11.2.2.4. Recent Developments and Future Outlook
  • 11.2.3. Roche
    • 11.2.3.1. Company Overview
    • 11.2.3.2. Financial Information
    • 11.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
    • 11.2.3.4. Recent Developments and Future Outlook
  • 11.2.4. Ypsomed
    • 11.2.4.1. Company Overview
    • 11.2.4.2. Financial Information
    • 11.2.4.3. Connected / Smart Drug Delivery Devices Portfolio
    • 11.2.4.4. Recent Developments and Future Outlook
• 11.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
  • 11.3.1. Nemera
    • 11.3.1.1. Company Overview
    • 11.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
  • 11.3.2. Sonceboz
    • 11.3.2.1. Company Overview
    • 11.3.2.2. Connected / Smart Drug Delivery Devices Portfolio

12. COMPANY PROFILES: CONNECTED / SMART DRUG DELIVERY DEVICE MANUFACTURERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

• 12.1. Chapter Overview
• 12.2. Leading Connected / Smart Drug Delivery Device Manufacturers
  • 12.2.1. Medtrum
    • 12.2.1.1. Company Overview
    • 12.2.1.2. Connected / Smart Drug Delivery Devices Portfolio
    • 12.2.1.3. Recent Developments and Future Outlook
  • 12.2.2. SOOIL Development
    • 12.2.2.1. Company Overview
    • 12.2.2.2. Connected / Smart Drug Delivery Devices Portfolio
    • 12.2.2.3. Recent Developments and Future Outlook
  • 12.2.3. EOFlow
    • 12.2.3.1. Company Overview
    • 12.2.3.2. Financial Information
    • 12.2.3.3. Connected / Smart Drug Delivery Devices Portfolio
    • 12.2.3.4. Recent Developments and Future Outlook
• 12.3. Other Prominent Connected / Smart Drug Delivery Device Manufacturers
  • 12.3.1. Eitan Medical
    • 12.3.1.1. Company Overview
    • 12.3.1.2. Connected / Smart Drug Delivery Devices Portfolio
  • 12.3.2. E3D Elcam Drug Delivery Device
    • 12.3.2.1. Company Overview
    • 12.3.2.2. Connected / Smart Drug Delivery Devices Portfolio

13. CLINICAL TRIAL ANALYSIS

• 13.1. Chapter Overview
• 13.2. Scope and Methodology
• 13.3. Connected / Smart Drug Delivery Devices and Add-on Sensors: Clinical Trial Analysis
  • 13.3.1. Analysis by Trial Registration Year
  • 13.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
  • 13.3.3. Analysis by Trial Phase
  • 13.3.4. Analysis by Trial Status
  • 13.3.5. Analysis by Type of Device
  • 13.3.6. Analysis by Type of Sponsor / Collaborator
  • 13.3.7. Analysis by Therapeutic Area
  • 13.3.8. Analysis by Study Design
  • 13.3.9. Leading Industry Players: Analysis by Number of Registered Trials
  • 13.3.10. Leading Connected / Smart Drug Delivery Devices and Add-on Sensors: Analysis by Number of Registered Trials
  • 13.3.11. Analysis by Geography
    • 13.3.11.1. Analysis of Number of Registered Trials by Trial Status and Geography
    • 13.3.11.2. Analysis of Enrolled Patient Population by Trial Status and Geography

14. PARTNERSHIPS AND COLLABORATIONS

• 14.1. Chapter Overview
• 14.2. Partnership Models
• 14.3. Connected / Smart Drug Delivery Devices: Partnerships and Collaborations
  • 14.3.1. Analysis by Year of Partnership
  • 14.3.2. Analysis by Type of Partnership
  • 14.3.3. Analysis by Year and Type of Partnership
  • 14.3.4. Analysis by Class of Device
  • 14.3.5. Analysis by Type of Integrated Device
  • 14.3.6. Analysis by Compatible Device
  • 14.3.7. Most Active Players: Analysis by Number of Partnerships
  • 14.3.8. Analysis by Geography
    • 14.3.8.1. Intracontinental and Intercontinental Deals
    • 14.3.8.2. Local and International Deals

15. FUNDING AND INVESTMENTS

• 15.1. Chapter Overview
• 15.2. Funding Models
• 15.3. Connected / Smart Drug Delivery Devices: Funding and Investments, since 2015
  • 15.3.1. Analysis by Year of Funding
  • 15.3.2. Analysis by Amount Invested
  • 15.3.3. Analysis by Type of Funding
    • 15.3.3.1. Analysis of Funding Instances
    • 15.3.3.2. Analysis of Amount Invested
  • 15.3.4. Analysis of Funding Instances by Year and Type of Funding
  • 15.3.5. Analysis by Class of Device
  • 15.3.6. Analysis by Geography
  • 15.3.7. Most Active Players: Analysis by Number of Funding Instances
  • 15.3.8. Most Active Players: Analysis by Amount Raised
  • 15.3.9. Leading Investors: Analysis by Number of Funding Instances
• 15.4. Summary of Funding and Investments
• 15.5. Connected / Smart Drug Delivery Devices: Funding and Investments, since 2021

16. VALUE CHAIN / COST PRICE ANALYSIS

• 16.1. Chapter Overview
• 16.2. Connected / Smart Drug Delivery Devices: Value Chain
• 16.3. Cost Distribution Across the Value Chain
  • 16.3.1. Concept Development and Proof of Concept
  • 16.3.2. Research and Product Development
  • 16.3.3. Conduct of Clinical Trials
  • 16.3.4. Regulatory Approvals
  • 16.3.5. Manufacturing and Product Assembly
  • 16.3.6. Application Development
  • 16.3.7. Marketing and Sales

17. REGULATORY LANDSCAPE FOR CONNECTED / SMART DRUG DELIVERY DEVICES

• 17.1. Chapter Overview
• 17.2. Regulatory Approval of Combination Products in North America
  • 17.2.1. Regulatory Approval of Combination Products in the US
    • 17.2.1.1. Overview
    • 17.2.1.2. Historical Background
    • 17.2.1.3. Role of Regulatory Bodies in Product Approval
  • 17.2.2. Regulatory Approval of Combination Products in Canada
    • 17.2.2.1. Overview
    • 17.2.2.2. Role of Regulatory Bodies in Product Approval
  • 17.2.3. Regulatory Approval of Combination Products in Mexico
    • 17.2.3.1. Overview
    • 17.2.3.2. Role of Regulatory Bodies in Product Approval
• 17.3. Regulatory Approval of Combination Products in Europe
  • 17.3.1. Regulatory Approval of Combination Products in EU5 Countries
    • 17.3.1.1. Overview
    • 17.3.1.2. Role of Regulatory Bodies in Product Approval
• 17.4. Regulatory Approval of Combination Products in Asia-Pacific
  • 17.4.1. Regulatory Approval of Combination Products in Japan
    • 17.4.1.1. Overview
    • 17.4.1.2. Role of Regulatory Bodies in Product Approval
  • 17.4.2. Regulatory Approval of Combination Products in China
    • 17.4.2.1. Overview
    • 17.4.2.2. Role of Regulatory Bodies in Product Approval
  • 17.4.3. Regulatory Approval of Combination Products in India
    • 17.4.3.1. Overview
    • 17.4.3.2. Role of Regulatory Bodies in Product Approval
  • 17.4.4. Regulatory Approval of Combination Products in South Korea
    • 17.4.4.1. Overview
    • 17.4.4.2. Role of Regulatory Bodies in Product Approval
  • 17.4.5. Regulatory Approval of Combination Products in Australia
    • 17.4.5.1. Overview
    • 17.4.5.2. Role of Regulatory Bodies in Product Approval
• 17.5. Regulatory Approval of Combination Products in Middle East and North Africa
  • 17.5.1. Regulatory Approval of Combination Products in Saudi Arabia
    • 17.5.1.1. Overview
    • 17.5.1.2. Role of Regulatory Bodies in Product Approval
  • 17.5.2. Regulatory Approval of Combination Products in United Arab Emirates
    • 17.5.2.1. Overview
    • 17.5.2.2. Role of Regulatory Bodies in Product Approval
• 17.6. Regulatory Approval of Combination Products in Latin America
  • 17.6.1. Regulatory Approval of Combination Products in Brazil
    • 17.6.1.1. Overview
    • 17.6.1.2. Role of Regulatory Bodies in Product Approval
  • 17.6.2. Regulatory Approval of Combination Products in Argentina
    • 17.6.2.1. Overview
    • 17.6.2.2. Role of Regulatory Bodies in Product Approval
• 17.7. Connected Devices: Other Measures for Testing Safety, Effectiveness and Performance
• 17.8. Ensuring Security of Data Captured
• 17.9. Concluding Remarks

18. CASE STUDIES: APPLICATION OF CONNECTED DRUG DELIVERY DEVICES TO IMPROVE MEDICATION ADHERENCE

• 18.1. Chapter Overview
• 18.2. Case Study I: Diabetes
  • 18.2.1. Disease Overview
  • 18.2.2. Key Statistics
  • 18.2.3. Economic Burden due to Non-Adherence
  • 18.2.4. Evolution of Connected / Smart Drug Delivery Devices for Improving Adherence
• 18.3. Case Study II: Asthma
  • 18.3.1. Disease Overview
  • 18.3.2. Key Statistics
  • 18.3.3. Economic Burden due to Non-Adherence
  • 18.3.4. Evolution of Connected / Smart Drug Delivery Devices for Improving Adherence

19. SWOT ANALYSIS

• 19.1. Chapter Overview
• 19.2. Strengths
  • 19.2.1. Ability to Minimize / Eliminate Medication Errors
  • 19.2.2. Economic Advantages
  • 19.2.3. Technological Advancements
• 19.3. Weaknesses
  • 19.3.1. Cybersecurity
  • 19.3.2. Stringent Regulatory Approvals
  • 19.3.3. High Developmental Costs
• 19.4. Opportunities
  • 19.4.1. Growing Prevalence of Chronic Disorders
  • 19.4.2. Increasing Adoption of Digital Health Technologies
  • 19.4.3. Rising Partnership and Investment Activity
• 19.5. Threats
  • 19.5.1. Material Compatibility Issues
  • 19.5.2. Availability of Alternative Drug Delivery Devices
  • 19.5.3. Concern Related to Product Recalls in Past
• 19.6. Comparison of SWOT Factors

20. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET

• 20.1. Chapter Overview
• 20.2. Assumptions and Methodology
• 20.3. Global Connected Drug Delivery Devices Market, till 2035
  • 20.3.1. Scenario Analysis
    • 20.3.1.1. Conservative Scenario
    • 20.3.1.2. Optimistic Scenario
• 20.4. Key Market Segmentations
• 20.5. Leading Industry Players

21. CONNECTED DRUG DELIVERY DEVICES MARKET, BY TYPE OF DEVICE

• 21.1. Chapter Overview
• 21.2. Assumptions and Methodology
• 21.3. Connected Drug Delivery Devices Market: Distribution by Type of Device, 2020, 2024 and 2035
  • 21.3.1. Connected Drug Delivery Devices Market for Connected / Smart Wearable Injectors, till 2035
  • 21.3.2. Connected Drug Delivery Devices Market for Connected / Smart Inhalers, till 2035
  • 21.3.3. Connected Drug Delivery Devices Market for Connected / Smart Pen Injectors, till 2035
  • 21.3.4. Connected Drug Delivery Devices Market for Connected / Smart Autoinjectors, till 2035
  • 21.3.5. Connected Drug Delivery Devices Market for Connected / Smart Needle-free Injection Systems, till 2035
• 21.4. Data Triangulation and Validation

22. CONNECTED DRUG DELIVERY DEVICES MARKET, BY MODE OF CONNECTIVITY

• 22.1. Chapter Overview
• 22.2. Assumptions and Methodology
• 22.3. Connected Drug Delivery Devices Market: Distribution by Mode of Connectivity, 2020, 2024 and 2035
  • 22.3.1. Connected Drug Delivery Devices Market for Bluetooth-enabled Devices, till 2035
  • 22.3.2. Connected Drug Delivery Devices Market for Near-field Communication-enabled Devices, till 2035
  • 22.3.3. Connected Drug Delivery Devices Market for Cellular-enabled Devices, till 2035
  • 22.3.4. Connected Drug Delivery Devices Market for Wide Area Network-enabled Devices, till 2035
• 22.4. Data Triangulation and Validation

23. CONNECTED DRUG DELIVERY DEVICES MARKET, BY ROUTE OF ADMINISTRATION

• 23.1. Chapter Overview
• 23.2. Assumptions and Methodology
• 23.3. Connected Drug Delivery Devices Market: Distribution by Route of Administration, 2020, 2024 and 2035
  • 23.3.1. Connected Drug Delivery Devices Market for Parenteral Administration, till 2035
  • 23.3.2. Connected Drug Delivery Devices Market for Inhalational Administration, till 2035
• 23.4. Data Triangulation and Validation

24. CONNECTED DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC AREA

• 24.1. Chapter Overview
• 24.2. Assumptions and Methodology
• 24.3. Connected Drug Delivery Devices Market: Distribution by Therapeutic Area, 2020, 2024 and 2035
  • 24.3.1. Connected Drug Delivery Devices Market for Metabolic Disorders, till 2035
  • 24.3.2. Connected Drug Delivery Devices Market for Respiratory Disorders, till 2035
  • 24.3.3. Connected Drug Delivery Devices Market for Autoimmune Disorders, till 2035
  • 24.3.4. Connected Drug Delivery Devices Market for Other Disorders, till 2035
• 24.4. Data Triangulation and Validation

25. CONNECTED DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHICAL REGIONS

• 25.1. Chapter Overview
• 25.2. Assumptions and Methodology
• 25.3. Connected Drug Delivery Devices Market: Distribution by Geographical Regions, 2020, 2024 and 2035
  • 25.3.1. Connected Drug Delivery Devices Market in North America, till 2035
    • 25.3.1.1. Connected Drug Delivery Devices Market in the US, till 2035
    • 25.3.1.2. Connected Drug Delivery Devices Market in Canada, till 2035
  • 25.3.2. Connected Drug Delivery Devices Market in Europe, till 2035
    • 25.3.2.1. Connected Drug Delivery Devices Market in the UK, till 2035
    • 25.3.2.2. Connected Drug Delivery Devices Market in Germany, till 2035
    • 25.3.2.3. Connected Drug Delivery Devices Market in France, till 2035
    • 25.3.2.4. Connected Drug Delivery Devices Market in Italy, till 2035
    • 25.3.2.5. Connected Drug Delivery Devices Market in Spain, till 2035
    • 25.3.2.6. Connected Drug Delivery Devices Market in Rest of the Europe, till 2035
  • 25.3.3. Connected Drug Delivery Devices Market in Asia-Pacific, till 2035
    • 25.3.3.1. Connected Drug Delivery Devices Market in China, till 2035
    • 25.3.3.2. Connected Drug Delivery Devices Market in India, till 2035
    • 25.3.3.3. Connected Drug Delivery Devices Market in Japan, till 2035
    • 25.3.3.4. Connected Drug Delivery Devices Market in Rest of the Asia-Pacific, till 2035
  • 25.3.4. Connected Drug Delivery Devices Market in Middle East and North Africa, till 2035
    • 25.3.4.1. Connected Drug Delivery Devices Market in Egypt, till 2035
    • 25.3.4.2. Connected Drug Delivery Devices Market in Israel, till 2035
    • 25.3.4.3. Connected Drug Delivery Devices Market in Saudi Arabia, till 2035
    • 25.3.4.4. Connected Drug Delivery Devices Market in Rest of the Middle East and North Africa, till 2035
  • 25.3.5. Connected Drug Delivery Devices Market in Latin America and Rest of the World, till 2035
    • 25.3.5.1. Connected Drug Delivery Devices Market in Brazil, till 2035
    • 25.3.5.2. Connected Drug Delivery Devices Market in Argentina, till 2035
    • 25.3.5.3. Connected Drug Delivery Devices Market in Other Countries, till 2035
• 25.4. Data Triangulation and Validation

26. CONCLUDING REMARKS

27. EXECUTIVE INSIGHTS

• 27.1. Chapter Overview
• 27.2. Phillips-Medisize
  • 27.2.1. Company Snapshot
  • 27.2.2. Interview Transcript: Candace Bowering, Senior Director, Global Strategic Marketing, Medical
• 27.3. Cognita Labs
  • 27.3.1. Company Snapshot
  • 27.3.2. Interview Transcript: Gaurav Patel, Co-founder and Chief Executive Officer
• 27.4. Portal Instruments
  • 27.4.1. Company Snapshot
  • 27.4.2. Interview Transcript: Patrick Anquetil, Founder and Chief Executive Officer
• 27.5. Enable Injections
  • 27.5.1. Company Snapshot
  • 27.5.2. Interview Transcript: Michael D. Hooven, Chief Executive Officer and President
• 27.6. Amiko
  • 27.6.1. Company Snapshot
  • 27.6.2. Interview Transcript: Duilio Macchi, Chief Executive Officer
• 27.7. Elcam Medical
  • 27.7.1. Company Snapshot
  • 27.7.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
• 27.8 West Pharmaceutical Services
  • 27.8.1. Company Snapshot
  • 27.8.2. Interview Transcript: Tiffany Burke, Director (Global Communications) and Graham Reynolds, Former Vice President (Strategic Partnerships and Business Development)
• 27.9. Avoset Health (acquired by Eitan Medical)
  • 27.9.1. Company Snapshot
  • 27.9.2. Interview Transcript: Shaul Eitan, Former Chief Executive Officer
• 27.10 Phillips-Medisize
  • 27.10.1. Company Snapshot
  • 27.10.2. Interview Transcript: Neil Williams, Former Director (Front-end Innovation and Head of Connected Health)
• 27.11. Sorrel Medical (acquired by LTS lohmann therapie-systeme)
  • 27.11.1. Company Snapshot
  • 27.11.2. Interview Transcript: Mindy Katz, Former Vice President (Marketing and Alliance Management)
• 27.12. etectRx
  • 27.12.1. Company Snapshot
  • 27.12.2. Interview Transcript: Anonymous, Advisor (Strategy and Business Development)

28. APPENDIX 1: TABULATED DATA

29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

30. APPENDIX 3: PARTNERSHIPS AND COLLABORATIONS, since 2015

관련자료